Spatial Genomics Transcriptomics Market,  Forecast to 2033

Spatial Genomics Transcriptomics Market

Spatial Genomics Transcriptomics Market By Technology (Spatial Transcriptomics, Spatial Genomics, In Situ Sequencing, In Situ Hybridization, Spatial Proteomics, Others); By Product Type (Instruments, Reagents & Kits, Software, Consumables, Services, Others); By Application (Cancer Research, Neuroscience, Immunology, Developmental Biology, Drug Discovery, Others); By End User (Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals, CROs, Others); By Workflow (Sample Preparation, Sequencing, Imaging, Bioinformatics Analysis, Data Interpretation, Others), By Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2026-2033

Report ID : 8430 | Publisher ID : Transpire | Published : Aug 2026 | Pages : 256 | Format: PDF/EXCEL

Revenue, 2025 USD 619.8 Million
Forecast, 2033 USD 2445.3 Million
CAGR, 2026 - 2033 18.72%
Report Coverage Global

Spatial Genomics Transcriptomics Market Summary:

As per Transpire Insight Analysis, the Spatial Genomics Transcriptomics Market size is estimated at USD 619.8 Million in 2025 and is anticipated to reach USD 2445.3 Million by 2033, growing at a CAGR of 18.72% from 2026 to 2033. Growth is fueled by the increasing need for high-resolution tissue examination, cancer studies, pharmaceutical research, and spatial technology.

The global spatial genomics and transcriptomics market is changing. It is moving away from being used for specialised research. Now it is being used for a range of things, such as examining tissue biology in great detail. Over the past few years, laboratories have started using spatial gene expression with other things like imaging and bioinformatics to see where things are happening inside tissue. They are also looking at cells and parts of cells. This is because they have tests and software that can handle a lot of information. One reason for this change is that people want to understand the area around tumours. They want to see how cells are interacting with each other, which's something that usual sequencing methods might not catch.

This new way of doing things is helping researchers connect what is happening with cells to where they're in the tissue. It is also helping them find targets for drugs and learn more about diseases. As it becomes easier to automate the work and look at the data, more people are using genomics and transcriptomics in areas like cancer research, neuroscience and drug development. The spatial genomics and transcriptomics market is getting bigger because of this.

Spatial Genomics Transcriptomics Market Size & Forecast:

  • Global Market Size 2025: USD 619.8 Million
  • Expected Market Value (2033): USD 2445.3 Million
  • Forecast CAGR (2026–2033): 18.72%
  • Leading Region in 2025: North America
  • Fastest Growing Region: Asia Pacific
  • Key Company Profiles: 10x Genomics, NanoString Technologies, Illumina, Bruker, Vizgen, Akoya Biosciences, Bio-Techne, Oxford Nanopore Technologies, Leica Biosystems, Thermo Fisher Scientific, Standard BioTools, Seven Bridges, Parse Biosciences, Pixelgen Technologies, Singular GenomicsSpatial Genomics Transcriptomics Market Size

Key Market Insights:

The market is evolving to be more inclusive of integrated spatial workflows where Spatial Transcriptomics forms the supplied market structure. Automation, multiomics and image analysis advances from various companies are helping scientists handle their tissue samples and analyse disease biology.

  • Spatial Transcriptomics is leading in the supplied market segmentation with 46% as there is an increased use of high-resolution RNA mapping in research workflows.
  • Spatial Genomics forms 22%, driven by increased need to link genomics signals with tissue localisation and the surrounding cells.
  • Reagents and Kits form 14%, bringing in revenue through recurring purchases from research labs as they run more tests on samples.
  • Cancer Research accounts for 10%, although with 18.9% CAGR, it is the fastest-growing application in the supplied market structure.
  • Software forms 5%, as there is an increasing requirement for image analysis, segmentation, visualisation, and bioinformatics in complex data sets.
  • Other applications form 3%, but there can always be unique workflows that allow vendors to capitalise on niche markets.
  • Companies are making advancements towards automation, higher plexing of assays and multiomic workflows, minimising manual efforts and increasing information extracted from each tissue sample.

What are the Key Drivers, Restraints, and Opportunities in the Spatial Genomics Transcriptomics Market?

Drivers

The market is becoming increasingly strong due to the fact that researchers require knowledge of molecular functioning combined with the location of each cell in tissues. Progress in single-cell analysis, multiplexing, and automation of imaging techniques makes spatial workflows more convenient for cancer, neuroscience, and immunology research. The increasing trend in cancer research is especially important since, according to the offered framework, cancer research represents the fastest-growing application area. As labs produce more data, the demand for equipment, reagents, and other services grows.

Restraints

The high cost of equipment, preparation processes, computations, and expertise needed limit use in the market. These factors remain challenges as the processes involved in spatial workflows are many, and there is potential for mistakes in sample preparation, imaging, segmentation, and analysis processes that could impact the outcome.

Opportunity

An opportunity remains in simple workflows combining spatial transcriptomics, proteomics, and artificial intelligence analysis of the data. Automation of equipment, cloud analysis, and increased throughput will allow for sales in the pharmaceutical industry and small research labs. Growth in the Asia Pacific will leave room for new installations and research collaborations.

What Has the Impact of Artificial Intelligence Been on the Spatial Genomics Transcriptomics Market?

There is currently an increased focus on incorporating artificial intelligence in spatial genomics and transcriptomics due to the fact that the platforms collect a huge amount of data from images, RNAs, and cells. AI can aid in the identification of cell boundaries, cell classification, elimination of any background noise, and assignment of molecules to the right cells. Machine learning algorithms can also enable researchers to identify spatial patterns in various samples, which would help them detect tumours, immune cell clusters, and gene expression changes that cannot be easily spotted by researchers. There has been a rise in the use of predictive models to associate spatial patterns with disease progression and response to drugs or other treatments. In terms of operations, automation of segmentation and analysis helps in eliminating repetitive tasks and speeds up the whole process of biological interpretation of images. Such developments have been witnessed in recent times when Vizgen launched an AI-powered cell-segmentation solution and when Bruker expanded its AI-based segmentations and AI-ready analysis capabilities.

Instance

In May 2025, the National Cancer Institute announced the introduction of Spotiphy, which is an artificial intelligence-enabled technology that has been funded by NCI and integrates both sequencing and imaging-based approaches to perform spatial transcriptomics. This technology can help in inferring gene expression at the single-cell level using large tissue sections. This is one of the examples of how artificial intelligence is enhancing data analysis in spatial transcriptomics and extracting more biological information from tissue samples.

https://www.cancer.gov/about-nci/organization/cbiit/news-events/news/2025/nci-funded-artificial-intelligence-ai-tool-powers-spatial-transcriptomics

Key Market Trends: 

There is a trend towards technology that enables gathering more biological data per tissue sample. Simultaneously, automation, multiomics, artificial intelligence-assisted analysis, and improved imaging are changing laboratory workflows.

  • Trend towards multiomics.The earlier laboratory workflows often worked with one molecular layer; now the platforms provide RNA, proteins, DNA, and imaging information.
  • Increased spatial resolution. There is a shift in the industry from the broad measurement of tissues to single-cell and subcellular analysis.
  • Increased automation. Manual sample preparation and image analysis are giving way to automated sample preparation and image analysis.
  • Growing trend towards whole-transcriptome workflows. Researchers are trying to obtain broader coverage of genes rather than using selected gene panels.
  • Artificial intelligence-assisted image analysis. Tools based on machine learning are increasingly used for cell segmentation, classification, and spatial pattern detection.
  • Trend towards 3D analysis. Recent technological advances enable spatial research not just in thin tissue slices but in three-dimensional volumes.
  • Growing focus on cancer research. Spatial technologies help understand cancer heterogeneity, cell-to-cell interactions, and changes due to treatments.
  • Growing integration of software. Vendors are integrating their instruments with bioinformatics and visualisation software platforms.

Spatial Genomics Transcriptomics Market Segmentation

By Technology

Spatial Transcriptomics is the biggest identified portion at 46%, and then it is followed by Spatial Genomics, which holds a 22% share in the market. The use of Spatial Transcriptomics is enabled by the technology’s ability to correlate gene expression information with the specific locations of tissue. The use of Spatial Genomics is driven by its potential to study genomic information in the context of the cellular and tissue environment.Spatial Genomics Transcriptomics Market Technology

By Product Type

 The Reagents and Kits contribute 14% to the supplied market segmentation, whereas the Software makes up 5%. The Instruments have a role to play in the market as well since they provide the technical platform for spatial imaging and molecular detection. Reagents and kits provide a recurring purchase opportunity during research, and software becomes increasingly important in dealing with images in order to analyse them.

By Application

The Cancer Research segment takes up 10% of the supplied market segmentation and is regarded as the fastest-growing application with 18.9% CAGR. This can be explained by the need to research the subject of tumour heterogeneity, interactions between immune cells and cancer cells and their local biological environment. Other applications, such as neuroscience, immunology, developmental biology, drug discovery, etc., are growing the addressable market through the use of spatial analysis.

By End User

academic and research institutes continue to be significant players as they conduct basic research and analyse new spatial technologies. The contribution of pharmaceutical and biotechnology firms is gaining importance with increasing use of spatial data in drug development, biomarker discovery, and translational research. Testing and research at hospitals and CROs are also possible but will depend on the complexity of the workflow, cost, required skill levels, and application of the data obtained.

By Workflow

the market includes Sample Preparation, Sequencing, Imaging, Bioinformatics Analysis, Data Interpretation, and other ancillary activities. Sample preparation will continue to be important as the quality of tissue determines the outcome of downstream processes, while sequencing and imaging contribute the molecular and spatial data respectively. Bioinformatics analysis and data interpretation are becoming increasingly important owing to the increase in size and complexity of datasets. The market framework provided does not have separate percentage values for each workflow segment, and so there are no unsupported workflow percentages included here.

What are the Key Use Cases Driving the Spatial Genomics Transcriptomics Market?

The essential use case is cancer research since spatial techniques can be used to uncover heterogeneity of tumours, localisations of immune cells, and distinctions between different parts of tissue. This enables biomarker discovery, profiling of diseases, and therapeutic assessment, which is consistent with the rapid growth of the cancer research market. Applications for spatial technology are becoming broader and are extending to neuroscience, immunology, developmental biology, and drug discovery, where localisation of cells and architecture of tissues affect biological results. For pharmaceutical companies, spatial data can help to comprehend mechanisms of diseases and treatment in the context of complicated tissue environment. New directions include spatial multiomics for translational medicine, AI-driven tissue analysis, and datasets for creating predictive models of cells and tissues. Analysis of datasets as a service will make this technique available for laboratories that lack special computing resources.

Report Metrics

Details

Market size value in 2025

USD 619.8 Million

Market size value in 2026

USD 735.7 Million

Revenue forecast in 2033

USD 2445.3 Million

Growth rate

CAGR of 18.72% from 2026 to 2033

Base year

2025

Historical data

2021 - 2024

Forecast period

2026 - 2033

Report coverage

Revenue forecast, competitive landscape, growth factors, and trends

Regional scope

United States; Canada; Mexico; United Kingdom; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; United Arab Emirates

Key company profiled

10x Genomics, NanoString Technologies, Illumina, Bruker, Vizgen, Akoya Biosciences, Bio-Techne, Oxford Nanopore Technologies, Leica Biosystems, Thermo Fisher Scientific, Standard BioTools, Seven Bridges, Parse Biosciences, Pixelgen Technologies, Singular Genomics

Customization scope

Free report customization (country, regional & segment scope). Avail customized purchase options to meet your exact research needs.

Report Segmentation

By Technology (Spatial Transcriptomics, Spatial Genomics, In Situ Sequencing, In Situ Hybridization, Spatial Proteomics, Others); By Product Type (Instruments, Reagents & Kits, Software, Consumables, Services, Others); By Application (Cancer Research, Neuroscience, Immunology, Developmental Biology, Drug Discovery, Others); By End User (Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals, CROs, Others); By Workflow (Sample Preparation, Sequencing, Imaging, Bioinformatics Analysis, Data Interpretation, Others)

Which Regions are Driving the Spatial Genomics Transcriptomics Market Growth?

North America

North America dominates the regional market with a 45% market share due to its existing research in biotechnology and pharmaceutical sectors, advanced laboratory setup, and significant investment in genomics techniques. The region also has an extensive number of research centres and organisations engaged in the development of spatial platforms. Therefore, early adaptation of high-resolution equipment and software is supported in the region.

  • In February 2025, Illumina launched a novel spatial transcriptomics solution which is supposed to help with whole-transcriptome profiling at cellular resolution over large tissues. The company also announced the development of a project with Broad Institute called the Spatial Flagship project to examine spatial data sets for biomedical research purposes.

Europe

Europe constitutes 29% of the supplied market but remains second to North America with regard to market share and a considerable research capability. The market share of the region is fueled by established institutions in the field of life sciences, research in the pharmaceutical sector, collaboration of universities with technology providers, and a wide network of research programs promoting the adoption of molecular analysis methods. Thus, Europe has a stable market for spatial genomics and transcriptomics platforms.

Asia Pacific

 Asia Pacific constitutes 20% of the supplied market and is the fastest-growing region with a 19.7% CAGR. Growth of the market is driven by rising investment in biotechnology research, increasing research infrastructure, and the development of applications in advanced genomics. The future potential of Asia Pacific is huge due to the increasing sophistication of spatial analysis workflows adopted by pharmaceutical, biotechnology, and academic laboratories.In June 2025, MGI has partnered with Negedia, located in Italy, to make access to Stereo-seq technology for spatial transcriptomics and DNBSEQ sequencing available for precision medicine and biomedical research needs.Spatial Genomics Transcriptomics Market Region

Who are the Key Players in the Spatial Genomics Transcriptomics Market, and how do they compete?

In the global spatial genomics and transcriptomics market, competition is becoming increasingly defined by resolution, assay diversity, process automation, analysis, and ability to combine multiple biological layers. Besides instrument-based competition, companies compete in reagents, software, services, and research collaborations. 10x Genomics enhances its competitive advantage through platform innovation and development of spatial solutions including Atera, a platform for whole-transcriptome spatial analysis at subcellular resolution. The company’s strategy is based on expanding spatial workflows and integrating them with the existing single-cell solution portfolio. Bruker pursues the portfolio strategy, combining spatial transcriptomics CosMx with GeoMx, CellScape, PaintScape, and AtoMx analysis. Differentiation in the company’s portfolio is provided by RNA, protein, genome, and AI-based analysis on multiple platforms. Vizgen pursues a strategy based on high resolution and multiomics, including MERFISH chemistry and MERSCOPE platforms. The company's expansion includes novel panel development, AI-based segmentation, volumetric tissue mapping, and additional services that will enable it to address cancer, neuroscience, and cell atlas applications. Overall, the current market strategy reflects the trend towards complete spatial workflows as opposed to individual measuring technologies.

Spatial Genomics Transcriptomics Market companies

Recent Development News 

In February 2026, Bruker extended its partnership with Noetik to utilise CosMx spatial data sets for tissue foundation models and biological simulations through AI. This partnership aims to be used for disease modelling and drug discovery through large-scale spatial data sets.

https://ir.bruker.com/press-releases

In April 2025, Vizgen commercially extended MERFISH 2.0 technology and launched improved OmniVUE panels, including ADC biomarkers, broadening its spatial multiomics technology for use in translational research and cancer studies.

https://vizgen.com

What Strategic Insights Define the Future of the Spatial Genomics Transcriptomics Market?

The market is moving towards spatial multiomics, increased throughput, automation, and 3D mapping of tissue. The primary strategic change will involve transitioning from generating spatial data to making biological and drug discovery decisions based on these datasets. An unappreciated threat will be that expensive instruments, reagents, computational tools, and infrastructure may constrain more sophisticated technologies to well-equipped labs. There is also the issue of workflow complexity, where variability in sample preparation and segmentation reduces study-to-study comparability. The biggest emerging opportunity will be the integration of spatial data with AI models, allowing for the interpretation of complex tissue structure and the development of predictive biomarkers. The vendors need to emphasise simplicity in workflows, open-source software solutions, validated analytical workflows, and collaborations with pharma and academic institutions. Organisations that are reducing hands-on processing while increasing data and biological quality are positioned to win as spatial technologies advance towards translational research.

By Technology

  • Spatial Transcriptomics
  • Spatial Genomics
  • In Situ Sequencing
  • In Situ Hybridization
  • Spatial Proteomics

By Product Type

  • Instruments
  • Reagents & Kits
  • Software
  • Consumables
  • Services

By Application

  • Cancer Research
  • Neuroscience
  • Immunology
  • Developmental Biology
  • Drug Discovery

By End User

  • Academic & Research Institutes
  • Pharmaceutical Companie
  • Biotechnology Companies
  • Hospitals
  • CROs

By Workflow

  • Sample Preparation
  • Sequencing
  • Imaging
  • Bioinformatics Analysis
  • Data Interpretation

Regional Outlook

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • Australia & New Zealand
  • South Korea
  • India
  • Rest of Asia Pacific

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East & Africa

  • Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Rest of the Middle East & Africa

Frequently Asked Questions

Find quick answers to common questions.

  •       10x Genomics
  •       NanoString Technologies
  •       Illumina
  •       Bruker
  •       Vizgen
  •       Akoya Biosciences
  •       Bio-Techne
  •       Oxford Nanopore Technologies
  •       Leica Biosystems
  •       Thermo Fisher Scientific
  •       Standard BioTools
  •       Seven Bridges
  •       Parse Biosciences
  •       Pixelgen Technologies
  •       Singular Genomics

About the Authors

Pankaj Ghogare Patil -Author TI

Pankaj Ghogare Patil

I am Pankaj Ghogare Patil, a Senior Research Analyst at Transpire Insight, specializing in the Pharmaceutical, Chemicals & Materials, Healthcare IT, and Biotechnology industry. My expertise lies in conducting comprehensive market research, analyzing industry trends, evaluating competitive landscapes, and translating complex data into actionable insights. At Transpire Insight, I closely follow emerging technologies, regulatory developments, and market innovations to create accurate, well-researched, and informative content that helps businesses and professionals make informed decisions. I am committed to producing credible, evidence-based articles that reflect industry best practices while making technical topics accessible and valuable for a broad audience.

Chakradhar Khansole -Author TI

Chakradhar Khansole

Chakradhar serves as the Research Director at Transpire Insight, bringing over 8 years of experience in technology, innovation, and strategic market intelligence. He specializes in transforming complex market data into actionable business insights that enable organizations to make informed, growth-oriented decisions. Recognized for his strategic vision and analytical expertise, Chakradhar leads high-impact research initiatives, delivering comprehensive market assessments, competitive intelligence, and forward-looking industry analysis.

Recently Published Reports